Study guide
3.1 IRB/IEC Functions and Oversight
Certified Clinical Research Coordinator CCRC
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Scientific Concepts and Research Design
1.1 Protocol Elements 1.2 Study Design and Objectives 1.3 Study Endpoints and Biostatistics
2 Chapter 2: Ethical Principles and Guidelines
2.1 Ethical Principles (Declaration of Helsinki, Belmont Report) 2.2 Informed Consent Process and Documentation 2.3 Vulnerable Populations and Assent
3 Chapter 3: IRB/IEC Oversight and Participant Safety
3.1 IRB/IEC Functions and Oversight 3.2 Adverse Event Classification and Reporting 3.3 Safety Monitoring and Safety Reporting
4 Chapter 4: Participant Rights and Ethics
4.1 Participant Rights and Confidentiality (HIPAA/GDPR) 4.2 Conflicts of Interest 4.3 Ethical Scenarios in Clinical Trials
5 Chapter 5: Product Development and Regulatory Framework
5.1 Drug and Device Development Phases 5.2 U.S. and International Regulatory Frameworks 5.3 Investigational Product Investigator's Brochure (IB)
6 Chapter 6: Investigational Product Accountability
6.1 Investigational Product Labeling and Storage 6.2 Investigational Product Receipt, Dispensing, and Accountability 6.3 Investigational Product Return and Destruction
7 Chapter 7: Regulatory Submissions and Actions
7.1 Regulatory Submissions (IND, NDA, IDE, PMA) 7.2 Regulatory Actions and Compliance 7.3 Pharmacokinetics and Pharmacodynamics in Product Development
8 Chapter 8: Clinical Trial Operations and GCP Principles
8.1 Introduction to ICH E6 GCP Principles (including R3 updates) 8.2 Investigator Responsibilities under GCP 8.3 Sponsor Responsibilities and Oversight
9 Chapter 9: Essential Documents and Site Qualification
9.1 Essential Documents (Pre-study, During, Post-study) 9.2 Site Selection and Qualification 9.3 Quality Management and Standard Operating Procedures (SOPs)
10 Chapter 10: Protocol Deviations and Amendments
10.1 Protocol Adherence and Compliance 10.2 Protocol Deviations and Violations 10.3 Protocol Amendments and Version Control
11 Chapter 11: Monitoring Visits and Audits
11.1 Monitoring Preparation and Visit Types 11.2 Monitoring Visits (SIV, IMV, COV) 11.3 Regulatory Inspections and Site Audits
12 Chapter 12: Study and Site Management - Startup
12.1 Site Startup Operations 12.2 Site Budget and Contract Management 12.3 Site Staffing, Training, and Documentation
13 Chapter 13: Enrollment and Recruitment
13.1 Enrollment Management and Strategies 13.2 Participant Recruitment and Retention 13.3 Participant Compensation and Ethics
14 Chapter 14: Daily Trial Coordination
14.1 Visit Scheduling and Logistics 14.2 Equipment Maintenance and Calibration 14.3 Specimen Handling and Shipping (IATA/dangerous goods)
15 Chapter 15: Quality Improvement and Site Closeout
15.1 Participant Safety Management 15.2 Quality Improvement and Site Audits Preparation 15.3 Study and Site Closeout Procedures
16 Chapter 16: Source Documentation and Case Report Forms
16.1 Source Documentation Standards (ALCOA-C) 16.2 Case Report Forms and eCRF Completion 16.3 Electronic Data Capture (EDC) Systems
17 Chapter 17: Data Management and Queries
17.1 Data Management Processes 17.2 Data Queries and Discrepancy Resolution 17.3 Data Correction and Audit Trails
18 Chapter 18: Data Privacy and Records Retention
18.1 Data Privacy and Confidentiality 18.2 Records Retention and Archiving 18.3 Compliance in Clinical Trial Informatics
3.1 IRB/IEC Functions and Oversight
Key Takeaways Explain This Topic AI
The primary purpose of an IRB/IEC is to protect the rights, safety, and well-being of human subjects involved in clinical research.
ICH E6(R3) recommends at least five IRB/IEC members, including one whose primary interest is not medical science and one independent of the institution; in the US, 21 CFR 56.107 requires five members, a scientist, a nonscientist and a non-affiliated member.
There are three main types of IRB review: Full Board, Expedited, and Exempt, each applying to different levels of risk and study designs.
Last updated: October 2026
Institutional Review Boards (IRB) and Independent Ethics Committees (IEC)
The cornerstone of clinical research ethics is the independent review of research protocols involving human subjects. In the United States, this reviewing body is typically referred to as an Institutional Review Board (IRB). Internationally, particularly under ICH GCP guidelines, it is known as an Independent Ethics Committee (IEC). While the terminology differs slightly depending on the regulatory framework, the core mandate remains identical: to safeguard the rights, safety, and well-being of all human research participants.
Regulatory bodies rely on IRBs and IECs to act as the primary gatekeepers for ethical research conduct. Before any clinical trial can commence, the investigator or sponsor must obtain written and dated approval or favorable opinion from the IRB/IEC for the trial protocol, written informed consent form, consent form updates, subject recruitment procedures (e.g., advertisements), and any other written information to be provided to subjects.
IRB Membership and Composition
To ensure a balanced, comprehensive, and unbiased review of clinical research, ICH E6(R3) (section 1.3.1) recommends a composition for the IRB/IEC, and in the United States FDA's 21 CFR 56.107 makes similar rules mandatory.
The board must consist of a reasonable number of members, who collectively have the qualifications and experience to review and evaluate the science, medical aspects, and ethics of the proposed trial. ICH E6(R3) recommends that the IRB/IEC include:
At least five members : Many institutional IRBs have more, so that quorums are easily met and diverse expertise is available.
At least one member whose primary area of interest is not in medical sciences : Examples include ethicists, lawyers, or clergy. Their role is to ensure the research is evaluated not just on its scientific merit, but on its ethical implications, fairness, and the clarity of subject-facing materials.
At least one member who is independent of the institution/investigator site : This unaffiliated member (sometimes a community representative) provides an objective perspective, free from institutional conflicts of interest or pressures to approve research that might financially benefit the site.
Only members who are independent of the investigator and the sponsor vote or give an opinion. The investigator and site staff may provide information on any aspect of the trial but do not take part in the IRB/IEC's decision or vote (ICH E6(R3) 1.3.1 and 1.3.5).
In the United States, 21 CFR 56.107 makes composition a requirement: at least five members, at least one member whose primary concerns are in the scientific area and one whose primary concerns are in nonscientific areas, and at least one member not otherwise affiliated with the institution.
Types of IRB Review
Clinical research protocols are not a monolith; they range from anonymous surveys to first-in-human gene therapies. To manage this spectrum, IRBs utilize different levels of review based on the degree of risk posed to participants. The concept of "minimal risk" is central to determining the appropriate review pathway. Minimal risk means that the probability and magnitude of harm or discomfort anticipated in the research are not greater in and of themselves than those ordinarily encountered in daily life or during the performance of routine physical or psychological examinations or tests.
Review Type Description Examples Risk Level
Full Board Review The protocol is reviewed and discussed at a convened meeting of the IRB where a quorum is present. A majority vote is required for approval. Phase I-III clinical trials, studies involving vulnerable populations, or interventions with significant physical/psychological risks. Greater than minimal risk
Expedited Review Review is conducted by the IRB chairperson or by one or more experienced reviewers designated by the chairperson. It does not require a convened meeting. Collection of blood samples by finger stick, non-invasive clinical data collection, or minor modifications to previously approved research. Not greater than minimal risk
Exempt Review Research that falls into specific regulatory categories that exempt it from the requirements of the Common Rule or FDA regulations. An IRB or designated institutional official must determine the exemption status. Educational tests, surveys, or retrospective chart reviews where data is completely de-identified. Less than minimal risk
Continuing Review and Ongoing Oversight
The IRB's responsibility does not end with the initial approval of a protocol. Ongoing oversight is legally required to ensure the continuous safety of participants and the ethical conduct of the trial.
Continuing Review: ICH E6(R3) leaves the frequency of continuing review to the IRB/IEC (1.4.4); in the United States, FDA requires continuing review at intervals appropriate to the degree of risk, but not less than once per year (21 CFR 56.109(f)). The investigator must submit a progress report detailing the number of subjects enrolled, a summary of adverse events, any protocol deviations, and any new literature or findings that might affect the study's risk/benefit ratio. If the IRB does not renew approval before the expiration date, all research activities (including subject treatments and data collection) must halt immediately, unless stopping the intervention would severely harm current participants.
Protocol Amendments: No deviation from, or change to, the protocol should be initiated without prior documented IRB/IEC approval of an appropriate amendment (ICH E6(R3) 1.4.7). There are two exceptions: a change necessary to eliminate an immediate hazard to participants, and, where applicable regulatory requirements allow, a change involving only logistical or administrative aspects of the trial. After an immediate-hazard deviation, the investigator informs the sponsor promptly and reports the hazard, the change and any proposed amendment to the IRB/IEC and, where applicable, to regulatory authorities (2.5.4 and 2.5.5).
Unanticipated Problems and Protocol Deviations: Clinical Research Coordinators (CRCs) play a crucial role in maintaining IRB compliance. If a protocol deviation occurs (e.g., a subject misses a required safety lab draw or is given an incorrect drug dose), it must be documented and, depending on institutional policy and the severity of the deviation, reported to the IRB. Furthermore, investigators are obligated to promptly report any unanticipated problems involving risks to subjects or others (UPIRSOs) to the IRB. This includes serious and unexpected adverse events related to the study intervention.
The Clinical Research Coordinator's Role with the IRB
The CRC is often the primary liaison between the investigator and the IRB. Responsibilities typically include preparing the initial submission packet (protocol, informed consent form, investigator's brochure, recruitment materials), drafting responses to IRB stipulations or questions, submitting prompt reports of adverse events and deviations, and ensuring continuing review applications are filed well before expiration deadlines. A CRC's meticulous attention to IRB documentation ensures the trial remains compliant and, most importantly, that participant safety is actively monitored.